Screener
Relmada Therapeutics, Inc. RLMD Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | As of / March 31, | As of |
|---|---|---|
| Total assets | $235,362,794 | $94,003,471 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,731,401 | $1,568,944 |
| Accrued expenses | 7,160,233 | 4,861,583 |
| Total current liabilities | 12,891,634 | 6,430,527 |
| Stock appreciation rights | 3,738,583 | 1,060,931 |
| Total liabilities | 16,630,217 | 7,491,458 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s accounts payable?
- Relmada Therapeutics, Inc. (RLMD) reported accounts payable of $5.73M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s accounts payable changed year-over-year?
- Relmada Therapeutics, Inc.'s accounts payable increased by 353.1% year-over-year, from $1.27M to $5.73M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s accounts payable has grown at a -28.4% compound annual growth rate (CAGR), from $8.35M to $1.57M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Relmada Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude